03.04.2012 - London companies PolyTherics and Spirogen collaborate for better antibody-drug-conjugates (ADCs) in the fight against cancer.
London – The buzz around antibody-drug-conjugates (ADCs), the weapons of choice in the fight against cancer, just became more blatant. After last week’s news that a novel ADC company had been founded in Switzerland PolyTherics Limited from London (UK) announced on 2 April that it would join in the treasure hunt for promising ADC candidates. Just like the Swiss ADC Therapeutics Sarl, London-seated PolyTherics relies on the cytotoxic agents provided by Spirogen Limited. The two companies want to combine PolyTherics’ linker technology TheraPEG™ with Spirogen’s potent cytotoxic pyrrolobenzodiazepines („PBDs“). The aim is to connect PBDs via the new linker to antibodys or antibody fragments in a site-specific manner. PolyTherics CEO John Burt is enthusiastic: „This is an exciting opportunity to combine our validated conjugation technology with Spirogen’s potentially best-in-class PBD warheads.“ Also Spirogen CEO Chris Martin is convinced the collaboration will bear fruit: „ADCs will represent a significant medical breakthrough in cancer therapy. PolyTherics’ TheraPEG™ conjugation technology will broaden the applications where our PBD warheads and linkers can create highly potent potentially market-leading ADC candidates.“ Spirogen’s PBDs are DNA minor groove binding agents, which bind and cross-link specific DNA-sites. They block cell division in the targeted (cancer) cells without distorting their DNA helix, thus avoiding the common phenomenon of emergent drug resistance.
29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.
24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.
23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.
16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.
15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.
10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more